HDAC9 and glioblastoma: As unvaryingly lethal as this tumor is, the potential of novel therapeutic agents must not be overlooked in HDAC inhibitors because any new therapy may provide a new chance at remission for glioblastoma patients who are in desperate need of novel approaches towards fighting their malignant condition.